Abstract:Introduction Lung cancer continues to be a common form of cancer worldwide and a primary contributor to cancer-related fatalities. Non-small cell lung cancer (NSCLC) is the most prevalent form, making up 80% to 85% of newly identified malignant lung tumours, and remains a major concern for worldwide health. Surgical resection is the preferred treatment for localised NSCLC, but more than one-third of patients present with locally advanced, unresectable tumours. Concurrent radiation therapy and chemotherapy are believed to offer the potential for prolonged disease-free and overall survival to those patients. However, the results are inconsistent, and systematic meta-analysis is lacking to evaluate its treatment effect comprehensively. Therefore, we will conduct a meta-analysis to evaluate the efficacy and safety of 3D-CRT concurrent chemotherapy in unresectable stage III NSCLC to provide evidence-based medical support for clinical treatment. Methods and analysis This systematic review and meta-analysis will adhere to the guidelines outlined in the PRISMA statement. Based on the predetermined criteria for inclusion, we will conduct a comprehensive search for randomised controlled trials (RCTs) examining the efficacy and safety of three-dimensional conformal radiation therapy (3D-CRT) concurrent chemotherapy in unresectable stage III NSCLC. The search will be performed across multiple databases including PubMed, Embase, Cochrane, Scopus and Web of Science from inception to 1 November 2024 using terms including NSCLC, 3D-CRT concurrent chemotherapy, radiation therapy, RCT and controlled clinical trial. Furthermore, relevant literature citations will be gathered, and relevant journals will be manually searched. The primary outcomes in the study were overall survival; progression-free survival; 1-, 3- and 5-year survival rates; event-free survival; and median survival time. Secondary outcomes included treatment effectiveness, all adverse events (AEs), all treatment-related adverse events (TRAEs), AEs (grade ≥3) and TRAEs (grade ≥3). Two separate reviewers will be responsible for screening, extracting data and evaluating quality. Our reviewers will perform subgroup analysis, sensitivity analysis and publication bias analysis to evaluate the heterogeneity and robustness. Review Manager 5.4 will be used for the analysis and synthesis process. The risk of bias will be assessed using the Cochrane Risk of Bias tool (RoB 2), and the Grading of Recommendations Assessment, Development and Evaluation will be employed to evaluate the study's overall evidence quality. Ethics and dissemination This study is based on a secondary analysis of the literature, so ethical review approval is not required. The final report will be published in a peer-reviewed journal. Trial registration

Multidisciplinary Combined Modality Therapy for Stage Ⅲ Non-Small Cell Lung Cancer

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Concurrent paclitaxel or/and carboplatin with radiotherapy for stageⅢnon-small cell lung cancer

Concomitant Chemotherapy and Radiotherapy for Inoperable Stage Ⅲ Non-Small Cell Lung Cancer

Different Chemotherapeutic Scheme Plus Radiation for Inoperable Stage III Non-Small Cell Lung Cancer

A Prospective,multicenter,phase Ⅱclinical Study of Three-Dimensionalradiotherapy with Concurrent Chemotherapy for Stage IV Non-Small-cell Lung Cancer-the Impact of Different Pathological Types on Survival (PPRA-RTOG003)

A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non …

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Late Course Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage Ⅲ Non-Small Cell Lung Cancer

Radiochemotherapy Combined with Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Locally Advanced Non-Small Cell Lung Cancer:A Preliminary Study

Multinational Randomized Phase Iii Trial With Or Without Consolidation Chemotherapy Using Docetaxel And Cisplatin After Concurrent Chemoradiation In Inoperable Stage Iii Non-Small-Cell Lung Cancer: Kcsg-Lu05-04

Study on Concomitant Radiotherapy and Chemotherapy Combinating with Endostatin for ⅢB and Ⅳ Stage Non-small Cell Lung Cancer

A Multicenter Randomized Phase III Trial to Compare Weekly Usage with Triweekly Usage of Docetaxel and Cisplatin in Concurrent Chemo-radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.

Efficacy and Safety of Definitive Chemoradiotherapy with or Without Induction Immune Checkpoint Inhibitors in Patients with Stage III Non-Small Cell Lung Cancer

Concurrent Albumin-Bound Paclitaxel And/Or Carboplatin With Radiation Therapy For The Treatment Of Locally Advanced Non-Small Cell Lung Cancer

A Prospective Phase II Study of Consolidation Chemotherapy after Concurrent Chemoradiotherapy for Oligometastatic Stage IV Non-Small Cell Lung Cancer

Expert Consensus on Treatment for Stage III Non‐small Cell Lung Cancer

Paclitaxel Combined with Three Dimensional-conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003

Retrospective analysis of induction concurrent chemoradiotherapy with weekly docetaxel and cisplatin followed by surgery for stage ⅢA-N2 non-small-cell lung cancer

Three-dimensional conformal radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: protocol for a systematic review and meta-analysis